Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

BAY 38-7271

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
BAY 38-7271
Legal status
Legal status
Identifiers
  • (−)-(R)-3-(2-Hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluorobutyl-1-sulfonate
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC20H21F3O5S
Molar mass430.44 g·mol−1
3D model (JSmol)
  • FC(F)(F)CCCS(=O)(=O)Oc3cccc(Oc1cccc2c1C[C@@H](C2)CO)c3
  • InChI=1S/C20H21F3O5S/c21-20(22,23)8-3-9-29(25,26)28-17-6-2-5-16(12-17)27-19-7-1-4-15-10-14(13-24)11-18(15)19/h1-2,4-7,12,14,24H,3,8-11,13H2/t14-/m1/s1 checkY
  • Key:XJURALZPEJKKOV-CQSZACIVSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Originally synthesized by chemist Wayne E. Kenney,BAY 38-7271 (KN 38-7271) is a drug which is acannabinoid receptor agonist developed byBayer AG. It hasanalgesic andneuroprotective effects and is used in scientific research, with proposed uses in the treatment oftraumatic brain injury.[1][2] It is afull agonist with around the same potency asCP 55,940 in animal studies, and has fairly high affinity for bothCB1 andCB2 receptors, withKi values of 2.91nM at CB1 and 4.24nM at CB2.[3][4] It has been licensed toKeyNeurotek Pharmaceuticals for clinical development,[5] and was inPhase II trials in 2008[6] but its development appears to have stopped.

References

[edit]
  1. ^Mauler F, Horváth E, De Vry J, Jäger R, Schwarz T, Sandmann S, et al. (2003)."BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury".CNS Drug Reviews.9 (4):343–58.doi:10.1111/j.1527-3458.2003.tb00259.x.PMC 6741701.PMID 14647528.
  2. ^Mauler F, Hinz V, Augstein KH, Fassbender M, Horváth E (October 2003). "Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271".Brain Research.989 (1):99–111.doi:10.1016/s0006-8993(03)03376-6.PMID 14519516.S2CID 20422282.
  3. ^Mauler F, Mittendorf J, Horváth E, De Vry J (July 2002). "Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties".The Journal of Pharmacology and Experimental Therapeutics.302 (1):359–68.doi:10.1124/jpet.302.1.359.PMID 12065738.
  4. ^De Vry J, Rüdiger Jentzsch K (December 2002). "Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist".European Journal of Pharmacology.457 (2–3):147–52.doi:10.1016/s0014-2999(02)02697-3.PMID 12464360.
  5. ^Pipeline
  6. ^KeyNeurotek Pharmaceuticals AG Reports Positive Phase I Data of Its Cannabinoid Receptor-Agonist
Phytocannabinoids
(comparison)
Cannabibutols
Cannabichromenes
Cannabicyclols
Cannabidiols
Cannabielsoins
Cannabigerols
Cannabiphorols
Cannabinols
Cannabitriols
Cannabivarins
Delta-8-tetrahydrocannabinols
Delta-9-tetrahydrocannabinols
Delta-10-Tetrahydrocannabinols
Miscellaneous cannabinoids
Active metabolites
Endocannabinoids
Synthetic
cannabinoid
receptor
agonists /
neocannabinoids
Classical cannabinoids
(dibenzopyrans)
Non-classical
cannabinoids
Adamantoylindoles
Benzimidazoles
Benzoylindoles
Cyclohexylphenols
Eicosanoids
Indazole-3-
carboxamides
Indole-3-carboxamides
Indole-3-carboxylates
Naphthoylindazoles
Naphthoylindoles
Naphthoylpyrroles
Naphthylmethylindenes
Naphthylmethylindoles
Phenylacetylindoles
Pyrazolecarboxamides
Tetramethylcyclo-
propanoylindazoles
Tetramethylcyclo-
propanoylindoles
Others
AllostericCBRTooltip Cannabinoid receptorligands
Endocannabinoid
enhancers
(inactivation inhibitors)
Anticannabinoids
(antagonists/inverse
agonists/antibodies)
Retrieved from "https://en.wikipedia.org/w/index.php?title=BAY_38-7271&oldid=1082421709"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp